Dr Floyd Hassenrueck
Dr Floyd Hassenrueck
Contact
Email
show email address
Dr Floyd Hassenrück is a Research Officer at the Murdoch Children's Research Institute, working with Professor Andrew Elefanty on disease modelling of Acute Myeloid/Lymphoid Leukaemias within the ReNEW program.
Floyd completed his B.Sc. in Applied Biology at the University of Applied Sciences Bonn-Rhein-Sieg. He was awarded an ERASMUS fellowship for practical training at the laboratory for Cell growth, Regeneration and Tissue Repair at the Universite Paris-Est Creteil, where he studied a pseudo peptide for the treatment of pancreatic cancer. During his M.Sc. Biomedical Sciences he started working in the laboratory for Preclinical Drug Assessment at the University Hospital Cologne, where he investigated monoclonal antibodies for the treatment of Chronic Lymphocytic Leukaemia in the context of Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).
In 2016 Floyd started his PhD at the University of Cologne under the supervision of Dr. Günter Krause and Professor Dr. Michael Hallek on the topic of PI3K inhibitors in the context of drug resistance and efficacy. After finishing his PhD he stayed in Cologne for a one year Postdoc position with Dr. Rocio Rebollido-Rios, where he complemented his in vitro studies of PI3Ks with computational methods, such as Molecular Dynamics Simulations (MDS).
Floyd took a six-month gap-year in 2022 during which he explored Europe on his bicycle.
Eventually, Floyd came to Melbourne, Australia to pursue his research interests in developing new models for haematologic malignancies using stem cells.
During his PhD Floyd volunteered as a student representative for his graduate school, the Interdisciplinary Program for Molecular Medicine, and organised and hosted many scientific meetings and retreats for fellow students. Furthermore, he was involved in the organisation of a summer school for pupils, where they had the opportunity of a four-week practical experience in research laboratories accompanied by a lecture series and various group activities.
Floyd completed his B.Sc. in Applied Biology at the University of Applied Sciences Bonn-Rhein-Sieg. He was awarded an ERASMUS fellowship for practical training at the laboratory for Cell growth, Regeneration and Tissue Repair at the Universite Paris-Est Creteil, where he studied a pseudo peptide for the treatment of pancreatic cancer. During his M.Sc. Biomedical Sciences he started working in the laboratory for Preclinical Drug Assessment at the University Hospital Cologne, where he investigated monoclonal antibodies for the treatment of Chronic Lymphocytic Leukaemia in the context of Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).
In 2016 Floyd started his PhD at the University of Cologne under the supervision of Dr. Günter Krause and Professor Dr. Michael Hallek on the topic of PI3K inhibitors in the context of drug resistance and efficacy. After finishing his PhD he stayed in Cologne for a one year Postdoc position with Dr. Rocio Rebollido-Rios, where he complemented his in vitro studies of PI3Ks with computational methods, such as Molecular Dynamics Simulations (MDS).
Floyd took a six-month gap-year in 2022 during which he explored Europe on his bicycle.
Eventually, Floyd came to Melbourne, Australia to pursue his research interests in developing new models for haematologic malignancies using stem cells.
During his PhD Floyd volunteered as a student representative for his graduate school, the Interdisciplinary Program for Molecular Medicine, and organised and hosted many scientific meetings and retreats for fellow students. Furthermore, he was involved in the organisation of a summer school for pupils, where they had the opportunity of a four-week practical experience in research laboratories accompanied by a lecture series and various group activities.
Dr Floyd Hassenrück is a Research Officer at the Murdoch Children's Research Institute, working with Professor Andrew Elefanty on disease modelling of Acute Myeloid/Lymphoid Leukaemias within the ReNEW program.
Floyd completed his B.Sc. in Applied...
Floyd completed his B.Sc. in Applied...
Dr Floyd Hassenrück is a Research Officer at the Murdoch Children's Research Institute, working with Professor Andrew Elefanty on disease modelling of Acute Myeloid/Lymphoid Leukaemias within the ReNEW program.
Floyd completed his B.Sc. in Applied Biology at the University of Applied Sciences Bonn-Rhein-Sieg. He was awarded an ERASMUS fellowship for practical training at the laboratory for Cell growth, Regeneration and Tissue Repair at the Universite Paris-Est Creteil, where he studied a pseudo peptide for the treatment of pancreatic cancer. During his M.Sc. Biomedical Sciences he started working in the laboratory for Preclinical Drug Assessment at the University Hospital Cologne, where he investigated monoclonal antibodies for the treatment of Chronic Lymphocytic Leukaemia in the context of Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).
In 2016 Floyd started his PhD at the University of Cologne under the supervision of Dr. Günter Krause and Professor Dr. Michael Hallek on the topic of PI3K inhibitors in the context of drug resistance and efficacy. After finishing his PhD he stayed in Cologne for a one year Postdoc position with Dr. Rocio Rebollido-Rios, where he complemented his in vitro studies of PI3Ks with computational methods, such as Molecular Dynamics Simulations (MDS).
Floyd took a six-month gap-year in 2022 during which he explored Europe on his bicycle.
Eventually, Floyd came to Melbourne, Australia to pursue his research interests in developing new models for haematologic malignancies using stem cells.
During his PhD Floyd volunteered as a student representative for his graduate school, the Interdisciplinary Program for Molecular Medicine, and organised and hosted many scientific meetings and retreats for fellow students. Furthermore, he was involved in the organisation of a summer school for pupils, where they had the opportunity of a four-week practical experience in research laboratories accompanied by a lecture series and various group activities.
Floyd completed his B.Sc. in Applied Biology at the University of Applied Sciences Bonn-Rhein-Sieg. He was awarded an ERASMUS fellowship for practical training at the laboratory for Cell growth, Regeneration and Tissue Repair at the Universite Paris-Est Creteil, where he studied a pseudo peptide for the treatment of pancreatic cancer. During his M.Sc. Biomedical Sciences he started working in the laboratory for Preclinical Drug Assessment at the University Hospital Cologne, where he investigated monoclonal antibodies for the treatment of Chronic Lymphocytic Leukaemia in the context of Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).
In 2016 Floyd started his PhD at the University of Cologne under the supervision of Dr. Günter Krause and Professor Dr. Michael Hallek on the topic of PI3K inhibitors in the context of drug resistance and efficacy. After finishing his PhD he stayed in Cologne for a one year Postdoc position with Dr. Rocio Rebollido-Rios, where he complemented his in vitro studies of PI3Ks with computational methods, such as Molecular Dynamics Simulations (MDS).
Floyd took a six-month gap-year in 2022 during which he explored Europe on his bicycle.
Eventually, Floyd came to Melbourne, Australia to pursue his research interests in developing new models for haematologic malignancies using stem cells.
During his PhD Floyd volunteered as a student representative for his graduate school, the Interdisciplinary Program for Molecular Medicine, and organised and hosted many scientific meetings and retreats for fellow students. Furthermore, he was involved in the organisation of a summer school for pupils, where they had the opportunity of a four-week practical experience in research laboratories accompanied by a lecture series and various group activities.
Top Publications
- Hassenrück, F, Farina-Morillas, M, Neumann, L, Landini, F, Blakemore, SJ, Rabipour, M, Alvarez-Idaboy, JR, Pallasch, CP, Hallek, M, Rebollido-Rios, R, et al. Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.. Commun Biol 6(1) : 603 2023 view publication
- Krause, G, Hassenrück, F, Hallek, M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.. Drug Des Devel Ther 12: 2577 -2590 2018 view publication
- Hassenrück, F, Knödgen, E, Göckeritz, E, Midda, SH, Vondey, V, Neumann, L, Herter, S, Klein, C, Hallek, M, Krause, G. Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors.. Biomed Res Int 2018: 1023490 2018 view publication
- Alawbathani, S, Batool, M, Fleckhaus, J, Hamad, S, Hassenrück, F, Hou, Y, Li, X, Salmanton-García, J, Ullah, S, Wieters, F, et al. A teaching tool about the fickle p value and other statistical principles based on real-life data.. Naunyn Schmiedebergs Arch Pharmacol 394(6) : 1315 -1319 2021 view publication
- Krause, G, Hassenrück, F, Hallek, M. Relevant Cytokines in the B Cell Lymphoma Micro-Environment.. Cancers (Basel) 12(9) : 2020 view publication
Page 1 of 2